에서 실시간으로 운영 중이에요! 자세히 알아보기
TNDM 아이콘

Tandem Diabetes Care

16.24 USD
-0.28
1.69%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
1일
-1.69%
5일
0.81%
1개월
-7.36%
3개월
-0.31%
6개월
-19.16%
연초 이후
-24.64%
1년
6.21%
5년
-86.77%
10년
-75.39%
 

소개: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.

직원 수: 2,500

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 35.7%
중립 50%
부정적 14.3%
중립
Zacks Investment Research
7일 전
Is it the Right Time to Hold TNDM Stock in Your Portfolio?
Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.
Is it the Right Time to Hold TNDM Stock in Your Portfolio?
중립
Business Wire
15일 전
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diab.
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
중립
Business Wire
19일 전
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
MILAN--(BUSINESS WIRE)---- $TNDM #T2D--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
긍정적
Zacks Investment Research
지난달
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
중립
Zacks Investment Research
지난달
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
긍정적
Benzinga
지난달
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
긍정적
MarketBeat
2개월 전
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
Tandem Diabetes Care NASDAQ: TNDM highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump.
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
부정적
Zacks Investment Research
2개월 전
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
긍정적
MarketBeat
2개월 전
Tandem Diabetes Care Q2 Earnings Call Highlights
Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.
Tandem Diabetes Care Q2 Earnings Call Highlights
중립
Seeking Alpha
2개월 전
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Lightweight Charts™를 사용해 가격 차트를 구현했어요.